- Home
- EPIX vs AGEN Comparison
EPIX vs AGEN Comparison
Compare EPIX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- AGEN
- Stock Information
- Founded
- EPIX 2009
- AGEN 1994
- Country
- EPIX Canada
- AGEN United States
- Employees
- EPIX N/A
- AGEN N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPIX Health Care
- AGEN Health Care
- Exchange
- EPIX Nasdaq
- AGEN Nasdaq
- Market Cap
- EPIX 65.3M
- AGEN 52.6M
- IPO Year
- EPIX N/A
- AGEN 2000
- Fundamental
- Price
- EPIX $1.72
- AGEN $2.91
- Analyst Decision
- EPIX Hold
- AGEN Buy
- Analyst Count
- EPIX 3
- AGEN 4
- Target Price
- EPIX $2.00
- AGEN $8.00
- AVG Volume (30 Days)
- EPIX 280.5K
- AGEN 830.5K
- Earning Date
- EPIX 05-08-2025
- AGEN 05-12-2025
- Dividend Yield
- EPIX N/A
- AGEN N/A
- EPS Growth
- EPIX N/A
- AGEN N/A
- EPS
- EPIX N/A
- AGEN N/A
- Revenue
- EPIX N/A
- AGEN $103,463,000.00
- Revenue This Year
- EPIX N/A
- AGEN $4.03
- Revenue Next Year
- EPIX N/A
- AGEN $5.57
- P/E Ratio
- EPIX N/A
- AGEN N/A
- Revenue Growth
- EPIX N/A
- AGEN N/A
- 52 Week Low
- EPIX $1.40
- AGEN $1.38
- 52 Week High
- EPIX $7.88
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- EPIX 52.43
- AGEN 59.81
- Support Level
- EPIX $1.67
- AGEN $2.87
- Resistance Level
- EPIX $1.79
- AGEN $3.16
- Average True Range (ATR)
- EPIX 0.08
- AGEN 0.35
- MACD
- EPIX -0.01
- AGEN 0.02
- Stochastic Oscillator
- EPIX 21.28
- AGEN 56.25
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).